リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「DIVERSE: Bayesian Data IntegratiVE learning for precise drug ResponSE prediction」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

DIVERSE: Bayesian Data IntegratiVE learning for precise drug ResponSE prediction

Guvencpaltun, Betul Kaski, Samuel Mamitsuka, Hiroshi 京都大学 DOI:10.1109/tcbb.2021.3065535

2022.07

概要

Detecting predictive biomarkers from multi-omics data is important for precision medicine, to improve diagnostics of complex diseases and for better treatments. This needs substantial experimental efforts that are made difficult by the heterogeneity of cell lines and huge cost. An effective solution is to build a computational model over the diverse omics data, including genomic, molecular, and environmental information. However, choosing informative and reliable data sources from among the different types of data is a challenging problem. We propose DIVERSE, a framework of Bayesian importance-weighted tri- and bi-matrix factorization(DIVERSE3 or DIVERSE2) to predict drug responses from data of cell lines, drugs, and gene interactions. DIVERSE integrates the data sources systematically, in a step-wise manner, examining the importance of each added data set in turn. More specifically, we sequentially integrate five different data sets, which have not all been combined in earlier bioinformatic methods for predicting drug responses. Empirical experiments show that DIVERSE clearly outperformed five other methods including three state-of-the-art approaches, under cross-validation, particularly in out-of-matrix prediction, which is closer to the setting of real use cases and more challenging than simpler in-matrix prediction. Additionally, case studies for discovering new drugs further confirmed the performance advantage of DIVERSE.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

[1] N. B. La Thangue and D. J. Kerr, “Predictive biomarkers: A para- digm shift towards personalized cancer medicine,” Nat. Rev. Clin. Oncol., vol. 8, no. 10, 2011, Art. no. 587.

[2] L. Zhang, X. Chen, N.-N. Guan, H. Liu, and J.-Q. Li, “A hybrid interpolation weighted collaborative filtering method for anti-can- cer drug response prediction,” Front. Pharmacol., vol. 9, 2018, Art. no. 1017.

[3] B. Gu€venc¸ Paltun, H. Mamitsuka, and S. Kaski, “Improving drug response prediction by integrating multiple data sources: matrix factorization, kernel and network-based approaches,” Briefings Bioinf., vol. 22, pp. 346–359, 2019.

[4] J. Barretina et al., “The cancer cell line encyclopedia enables pre- dictive modelling of anticancer drug sensitivity,” Nature, vol. 483, no. 7391, pp. 603–607, 2012.

[5] M. P. Menden et al. “Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties,” PLoS One, vol. 8, no. 4, 2013, Art. no. e61318.

[6] K. P. Murphy, Machine Learning: A Probabilistic Perspective. Cam- bridge, MA, USA: MIT Press, 2012.

[7] J. C. Costello et al., “A community effort to assess and improve drug sensitivity prediction algorithms,” Nat. Biotechnol., vol. 32, no. 12, 2014, Art. no. 1202.

[8] H. Liu, Y. Zhao, L. Zhang, and X. Chen, “Anti-cancer drug response prediction using neighbor-based collaborative filtering with global effect removal,” Mol. Ther.-Nucleic Acids, vol. 13, pp. 303–311, 2018.

[9] N.-N. Guan, Y. Zhao, C.-C. Wang, J.-Q. Li, X. Chen, and X. Piao, “Anticancer drug response prediction in cell lines using weighted graph regularized matrix factorization,” Mol. Ther.-Nucleic Acids, vol. 17, pp. 164–174, 2019.

[10] M. Ammad-ud din et al., “Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization,” Bioinformatics, vol. 32, no. 17, pp. i455–i463, 2016.

[11] L. Wang, X. Li, L. Zhang, and Q. Gao, “Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization,” BMC Cancer, vol. 17, no. 1, 2017, Art. no. 513.

[12] N. Fujita, S. Mizuarai, K. Murakami, and K. Nakai, “Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses,” Sci. Rep., vol. 8, no. 1, pp. 1– 10, 2018.

[13] N. Zhang, H. Wang, Y. Fang, J. Wang, X. Zheng, and X. S. Liu, “Predicting anticancer drug responses using a dual-layer inte- grated cell line-drug network model,” PLoS Comput. Biol., vol. 11, no. 9, 2015, Art. no. e1004498.

[14] Z. Stanfield, M. Cos¸ kun, and M. Koyutu€rk, “Drug response pre- diction as a link prediction problem,” Sci. Rep., vol. 7, 2017, Art. no. 40321.

[15] F. Zhang, M. Wang, J. Xi, J. Yang, and A. Li, “A novel heteroge- neous network-based method for drug response prediction in can- cer cell lines,” Sci. Rep., vol. 8, no. 1, pp. 1–9, 2018.

[16] A. Cichonska et al., “Learning with multiple pairwise kernels for drug bioactivity prediction,” Bioinformatics, vol. 34, no. 13, pp. i509–i518, 2018.

[17] H. Sharifi-Noghabi, O. Zolotareva, C. C. Collins, and M. Ester, “Moli: Multi-omics late integration with deep neural networks for drug response prediction,” Bioinformatics, vol. 35, no. 14, pp. i501–i509, 2019.

[18] V. Y. Tan and C. F´evotte, “Automatic relevance determination in nonnegative matrix factorization with the/spl beta/-divergence,” IEEE Trans. Pattern Anal. Mach. Intell., vol. 35, no. 7, pp. 1592– 1605, Jul. 2013.

[19] T. Brouwer and P. Lio, “Bayesian hybrid matrix factorisation for data integration,” in Proc. 20th Int. Conf. Artif. Intell. Statist., 2017, pp. 557–566.

[20] D. Zhang, S. Chen, and Z.-H. Zhou, “Two-dimensional non-negative matrix factorization for face representation and recognition,” in Proc. Int. Workshop Anal. Model. Faces Gestures, 2005, pp. 350–363.

[21] W. Yang et al., “Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells,” Nucleic Acids Res., vol. 41, no. D1, pp. D955–D961, 2012.

[22] S. Kim et al., “Pubchem substance and compound databases,” Nucleic Acids Res., vol. 44, no. D1, pp. D1202–D1213, 2015.

[23] A. Gaulton et al., “The chembl database in 2017,” Nucleic Acids Res., vol. 45, no. D1, pp. D945–D954, 2017.

[24] D. Szklarczyk et al., “The string database in 2011: Functional inter- action networks of proteins, globally integrated and scored,” Nucleic Acids Res., vol. 39, no. suppl_1, pp. D561–D568, 2010.

[25] M. Ammad-Ud-Din et al., “Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization,” J. Chem. Inf. Model., vol. 54, no. 8, pp. 2347–2359, 2014.

[26] J. Chen, H. Peng, G. Han, H. Cai, and J. Cai, “HOGMMNC: A higher order graph matching with multiple network constraints model for gene–drug regulatory modules identification,” Bioinfor- matics, vol. 35, no. 4, pp. 602–610, 2019.

[27] J. Huang, J. Chen, B. Zhang, L. Zhu, and H. Cai, “Evaluation of gene–drug common module identification methods using phar- macogenomics data,” Briefings Bioinf., Jun. 2020, doi: 10.1093/bib/ bbaa087.

[28] J. Cai, H. Cai, J. Chen, and X. Yang, “Identifying “many-to-many” relationships between gene-expression data and drug-response data via sparse binary matching,” IEEE/ACM Trans. Comput. Biol. Bioinformatics, vol. 17, no. 1, pp. 165–176, Jan./Feb. 2020.

[29] X. Chen, B. Ren, M. Chen, Q. Wang, L. Zhang, and G. Yan, “NLLSS: predicting synergistic drug combinations based on semi- supervised learning,” PLoS Comput. Biol., vol. 12, no. 7, 2016, Art. no. e1004975.

参考文献をもっと見る